Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting.

Joshua F BakerCatherine BakewellAra DikranianGordon LamJacqueline O'BrienPage C MooreMiao YuPeter HurKarim Richard Masri

Published in: Rheumatology and therapy (2024)

In this real-world population of patients with RA initiating IFX-dyyb, the majority switched from IFX-REF or a non-IFX biologic/tsDMARD. CDAI remained stable in patients switching from IFX-REF/IFX biosimilar and improved in patients switching from a non-IFX biologic/tsDMARD and in biologic/tsDMARD-naïve patients.

Keyphrases

end stage renal disease
rheumatoid arthritis
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
type diabetes
metabolic syndrome
patient reported outcomes
ankylosing spondylitis